$1.82
0.052.82%
In chiusura: -
$1.82
0.000.00%
After hour: 5:47 PM EDT
Comments
Loading...
Stime degli utili, EPS e fatturato
Gain Therapeutics segnala gli utili su base trimestrale. Questi report sugli utili trimestrali offrono agli investitori uno sguardo ai risultati finanziari di un'azienda per un periodo di 3 mesi. I report sugli utili includono quasi sempre i risultati EPS e i ricavi.
Data degli utili
nov 13
Stima EPS
$-0.150
Stima dei ricavi trimestrali
–
Ricavi annuali
(a partire da giu 30)
(a partire da giu 30)
–
Analizza lo storico degli utili di Gain Therapeutics utilizzando ordinamenti e filtri avanzati.
Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
GANX | Gain Therapeutics | -$0.17 | -$0.15 | — | — | $0.00 | — | — | — | 11/13/2025 | |
GANX | Gain Therapeutics | -$0.42 | -$0.17 | -$0.19 | -11.76% | $0.00 | — | $0.00 | — | 08/12/2025 | |
GANX | Gain Therapeutics | -$0.22 | -$0.17 | -$0.16 | 5.88% | $0.00 | $33.33K | $0.00 | -100.00% | 05/14/2025 | |
GANX | Gain Therapeutics | -$0.29 | -$0.17 | -$0.11 | 35.29% | $0.00 | $30.00K | $0.00 | -100.00% | 03/27/2025 | |
GANX | Gain Therapeutics | -$0.37 | -$0.21 | -$0.17 | 19.05% | $0.00 | — | $0.00 | — | 11/14/2024 | |
GANX | Gain Therapeutics | -$0.62 | -$0.20 | -$0.42 | -110.00% | $0.00 | $400.00K | $0.00 | -100.00% | 08/08/2024 | |
GANX | Gain Therapeutics | -$0.43 | -$0.29 | -$0.22 | 24.14% | $55.18K | $30.00K | $0.00 | -100.00% | 05/14/2024 | |
GANX | Gain Therapeutics | -$0.39 | -$0.32 | -$0.29 | 9.38% | $0.00 | $320.00K | $0.00 | -100.00% | 03/26/2024 | |
GANX | Gain Therapeutics | -$0.38 | -$0.45 | -$0.37 | 17.78% | $0.00 | — | $0.00 | — | 11/14/2023 | |
GANX | Gain Therapeutics | -$0.43 | -$0.31 | -$0.62 | -100.00% | $95.10K | $1.01M | $0.00 | -100.00% | 08/10/2023 | |
GANX | Gain Therapeutics | -$0.28 | — | -$0.43 | — | $45.00K | — | $55.18K | — | 05/12/2023 | |
GANX | Gain Therapeutics | -$0.26 | -$0.38 | -$0.39 | -2.63% | $43.21K | $10.00K | $0.00 | -100.00% | 03/23/2023 | |
GANX | Gain Therapeutics | -$0.39 | -$0.46 | -$0.38 | 17.39% | $27.34M | $60.00K | $0.00 | -100.00% | 11/10/2022 | |
GANX | Gain Therapeutics | -$0.30 | -$0.31 | -$0.43 | -38.71% | $89.71M | $30.00K | $95.10K | 217.01% | 08/08/2022 | |
GANX | Gain Therapeutics | -$0.50 | -$0.37 | -$0.28 | 24.32% | $5.27K | $40.00K | $45.00K | 12.50% | 05/16/2022 | |
GANX | Gain Therapeutics | -$0.53 | -$0.49 | -$0.26 | 46.94% | $9.14K | $50.00K | $43.21K | -13.58% | 03/24/2022 | |
GANX | Gain Therapeutics | -$0.25 | -$0.36 | -$0.39 | -8.33% | $6.70K | $10.00K | $27.34K | 173.45% | 11/12/2021 | |
GANX | Gain Therapeutics | -$0.27 | -$0.30 | -$0.30 | 0.00% | — | — | $89.71K | — | 08/11/2021 | |
GANX | Gain Therapeutics | -$0.29 | -$0.19 | -$0.50 | -163.16% | $6.67M | — | $5.27K | — | 05/10/2021 |
Gain Therapeutics (GANX) Guadagno per azione
Importo a sorpresa sugli utili trimestrali
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q2 | 2025-08-12 | $-0.19 | $-0.17 | -11.8 % |
| Q1 | 2025-05-14 | $-0.16 | $-0.17 | 5.88 % |
| Q4 | 2025-03-27 | $-0.11 | $-0.17 | 35.3 % |
| Q3 | 2024-11-14 | $-0.17 | $-0.21 | 19.1 % |
Gain Therapeutics (GANX) Entrate
Importo sorpresa sulle entrate trimestrali
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q1 | 2025-05-14 | $0 | $33.33K | -100.0 % |
| Q4 | 2025-03-27 | $0 | $30.00K | -100.0 % |
| Q2 | 2024-08-08 | $0 | $400.00K | -100.0 % |
| Q1 | 2024-05-14 | $0 | $30.00K | -100.0 % |
FAQ
Quando Gain Therapeutics (NASDAQ:GANX) riporterà gli utili?
Si prevede che Gain Therapeutics (GANX) fornisca risultati il novembre 13, 2025. Gli ultimi risultati sono stati pubblicati il agosto 12, 2025 per il Q2.
Quali sono stati gli ultimi utili per azione (EPS) di Gain Therapeutics (NASDAQ:GANX)?
L'EPS effettivo era $-0.19, che mancato la stima di $-0.17.
Quali sono state le entrate di Gain Therapeutics (NASDAQ:GANX)?
Le entrate effettive sono state $0K, che centrato la stima di $0K.
Sfoglia stime sugli utili, EPS e ricavi su tutte le azioni.